Moflomycin | CAS#107430-03-5 | antileukemic

MedKoo Cat#: 584401 | Name: Moflomycin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Moflomycin is an anthracycline derivative that exhibits a higher antileukemic activity compared to other anthracyclines, such as daunorubicin and doxorubicin. The higher antileukemic activity of this compound are from greater stimulation of topoisomerase II-mediated DNA cleavage and higher molecular stability induced by the presence of an iodine atom.

Chemical Structure

Moflomycin

CAS#107430-03-5

Theoretical Analysis

MedKoo Cat#: 584401

Name: Moflomycin

CAS#: 107430-03-5

Chemical Formula: C25H25IO10

Exact Mass: 612.0492

Molecular Weight: 612.37

Elemental Analysis: C, 49.03; H, 4.12; I, 20.72; O, 26.13

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Moflomycin; F 860191; F-860191; F860191

IUPAC/Chemical Name

5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxymethyl)-, (7S,9S)-

InChi Key

IJWZCUDUUDYUBR-IWGZIANCSA-N

InChi Code

InChI=1S/C25H25IO10/c1-9-18(28)23(33)17(26)24(35-9)36-13-7-25(34,8-27)6-12-14(13)22(32)16-15(21(12)31)19(29)10-4-2-3-5-11(10)20(16)30/h2-5,9,13,17-18,23-24,27-28,31-34H,6-8H2,1H3/t9-,13-,17+,18-,23-,24-,25-/m0/s1

SMILES Code

O=C(C1=C2C(O)=C3C[C@](CO)(O)C[C@H](O[C@H]4[C@H](I)[C@@H]([C@H]([C@H](C)O4)O)O)C3=C1O)C5=CC=CC=C5C2=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 612.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Andrivon W, Monneret C, Nafziger J, Florent JC, Guillosson JJ. A new anthracycline with potent anti-leukemic activity overcomes P-glycoprotein multidrug resistance. Leuk Res. 1998 Aug;22(8):719-25. PubMed PMID: 9680099. 2: Andrivon W, Callais F, Nafziger J, Monneret C, Guillosson JJ. A new anthracycline with potent antileukemic activity exhibits reduced mutagenicity. Mutat Res. 1995 Oct;344(3-4):135-40. PubMed PMID: 7491131. 3: Florent JC, Genot A, Monneret C. Synthesis and antitumor activity of new anthracyclines. J Antibiot (Tokyo). 1989 Dec;42(12):1823-30. Erratum in: J Antibiot (Tokyo) 1990 Mar;43(3):C-1. PubMed PMID: 2621164. 4: Nafziger J, Auclair C, Florent JC, Guillosson JJ, Monneret C. Pharmacological and physicochemical properties of a new anthracycline with potent antileukemic activity. Leuk Res. 1991;15(8):709-13. PubMed PMID: 1654481. 5: Andrivon W, Saucier JM, Auclair C, Monneret C, Florent JC, Guillosson JJ, Nafziger J. Enhanced topoisomerase II-induced DNA breaks and free radical production by a new anthracycline with potent antileukemic activity. Leuk Res. 1996 Feb;20(2):119-26. PubMed PMID: 8628010.